Citadel Advisors’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-591,802
| Closed | -$20M | – | 14005 |
|
|
2025
Q4 | $20M | Buy |
591,802
+576,272
| +3,711% | +$17.9M | ﹤0.01% | 2335 |
|
|
2025
Q3 | $401K | Buy |
+15,530
| New | +$203K | ﹤0.01% | 9666 |
|
|
2025
Q2 | – | Sell |
-9,072
| Closed | -$69.2K | – | 14624 |
|
|
2025
Q1 | $88.5K | Buy |
9,072
+9,059
| +69,685% | +$89.1K | ﹤0.01% | 11638 |
|
|
2024
Q4 | $158 | Buy |
+13
| New | +$165 | ﹤0.01% | 14373 |
|
|
2024
Q2 | – | Sell |
-30,223
| Closed | -$1.4M | – | 15196 |
|
|
2024
Q1 | $2.17M | Buy |
30,223
+17,827
| +144% | +$2.48M | ﹤0.01% | 5359 |
|
|
2023
Q4 | $2.46M | Sell |
12,396
-785
| -6% | -$97.2K | ﹤0.01% | 4997 |
|
|
2023
Q3 | $1.75M | Sell |
13,181
-5,598
| -30% | -$914K | ﹤0.01% | 5469 |
|
|
2023
Q2 | $2.81M | Buy |
18,779
+5,948
| +46% | +$926K | ﹤0.01% | 4581 |
|
|
2023
Q1 | $1.88M | Buy |
12,831
+4,266
| +50% | +$863K | ﹤0.01% | 5509 |
|
|
2022
Q4 | $1.36M | Sell |
8,565
-7,972
| -48% | -$1.28M | ﹤0.01% | 6232 |
|
|
2022
Q3 | $3.18M | Buy |
16,537
+14,863
| +888% | +$2.81M | ﹤0.01% | 4690 |
|
|
2022
Q2 | $244K | Sell |
1,674
-7,491
| -82% | -$998K | ﹤0.01% | 10271 |
|
|
2022
Q1 | $1.61M | Buy |
+9,165
| New | +$1.73M | ﹤0.01% | 6572 |
|
|
2021
Q4 | – | Sell |
-1,328
| Closed | -$355K | – | 14569 |
|
|
2021
Q3 | $330K | Buy |
+1,328
| New | +$351K | ﹤0.01% | 10860 |
|
Citadel Advisors's RAPT Position: Q1 2026 in Review
Citadel Advisors sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 591,802 shares — an estimated $20M sold.
Citadel Advisors first reported a position in RAPT in Q3 2021 and held it in 14 quarters. The position peaked at $20M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Citadel Advisors reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 591,802 RAPT Therapeutics shares in Q1 2026, an estimated $20M.
- Citadel Advisors first reported a position in RAPT Therapeutics in Q3 2021 and held it in 14 quarters.
- Citadel Advisors's RAPT Therapeutics position peaked at $20M in Q4 2025.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.